Theresa Grover
Concepts (330)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units, Neonatal | 32 | 2025 | 253 | 3.700 |
Why?
| | Hernias, Diaphragmatic, Congenital | 15 | 2024 | 201 | 3.640 |
Why?
| | Extracorporeal Membrane Oxygenation | 6 | 2021 | 291 | 1.630 |
Why?
| | Infant, Premature | 12 | 2025 | 566 | 1.540 |
Why?
| | Infant, Newborn | 53 | 2025 | 6032 | 1.500 |
Why?
| | Cross Infection | 3 | 2025 | 250 | 1.380 |
Why?
| | Bacterial Infections | 2 | 2025 | 250 | 1.300 |
Why?
| | Catheterization, Central Venous | 5 | 2021 | 111 | 1.220 |
Why?
| | Bronchopulmonary Dysplasia | 10 | 2024 | 382 | 1.160 |
Why?
| | Urinary Tract Infections | 4 | 2025 | 188 | 1.080 |
Why?
| | Pulmonary Circulation | 15 | 2011 | 429 | 0.960 |
Why?
| | Enteral Nutrition | 4 | 2025 | 201 | 0.900 |
Why?
| | Mycoses | 1 | 2025 | 79 | 0.900 |
Why?
| | Gestational Age | 15 | 2025 | 902 | 0.870 |
Why?
| | Central Venous Catheters | 4 | 2021 | 51 | 0.860 |
Why?
| | Catheter-Related Infections | 4 | 2017 | 90 | 0.790 |
Why?
| | Length of Stay | 8 | 2025 | 1205 | 0.660 |
Why?
| | Quality Improvement | 9 | 2024 | 1163 | 0.650 |
Why?
| | Catheterization, Peripheral | 1 | 2021 | 109 | 0.640 |
Why?
| | Hypertension, Pulmonary | 11 | 2021 | 1905 | 0.630 |
Why?
| | Bottle Feeding | 1 | 2019 | 21 | 0.620 |
Why?
| | Fetus | 14 | 2020 | 806 | 0.610 |
Why?
| | Infant Formula | 1 | 2019 | 75 | 0.590 |
Why?
| | Vascular Endothelial Growth Factor A | 6 | 2007 | 543 | 0.570 |
Why?
| | Bacteremia | 4 | 2024 | 212 | 0.560 |
Why?
| | Practice Guidelines as Topic | 6 | 2024 | 1572 | 0.560 |
Why?
| | Lung | 10 | 2011 | 4063 | 0.550 |
Why?
| | Postoperative Complications | 4 | 2021 | 2639 | 0.550 |
Why?
| | Infant | 24 | 2024 | 9395 | 0.540 |
Why?
| | Parenteral Nutrition, Total | 1 | 2017 | 26 | 0.540 |
Why?
| | Weight Gain | 2 | 2017 | 519 | 0.510 |
Why?
| | Vasodilation | 11 | 2011 | 496 | 0.510 |
Why?
| | Gastroschisis | 3 | 2024 | 25 | 0.510 |
Why?
| | Sheep | 20 | 2011 | 856 | 0.500 |
Why?
| | Intensive Care, Neonatal | 4 | 2020 | 40 | 0.480 |
Why?
| | Retrospective Studies | 25 | 2025 | 15510 | 0.470 |
Why?
| | High-Frequency Ventilation | 1 | 2015 | 45 | 0.470 |
Why?
| | Developmental Disabilities | 1 | 2018 | 262 | 0.460 |
Why?
| | Infant, Premature, Diseases | 2 | 2024 | 100 | 0.460 |
Why?
| | Intersectoral Collaboration | 1 | 2015 | 60 | 0.450 |
Why?
| | Patient Education as Topic | 1 | 2019 | 761 | 0.430 |
Why?
| | Nitric Oxide Synthase | 9 | 2006 | 240 | 0.410 |
Why?
| | Tracheostomy | 3 | 2024 | 132 | 0.410 |
Why?
| | Anti-Bacterial Agents | 4 | 2024 | 1798 | 0.400 |
Why?
| | Endothelial Growth Factors | 2 | 2002 | 64 | 0.400 |
Why?
| | Hospitalization | 3 | 2021 | 2184 | 0.390 |
Why?
| | Lymphokines | 2 | 2002 | 131 | 0.390 |
Why?
| | Patient Discharge | 6 | 2025 | 894 | 0.370 |
Why?
| | Surgical Procedures, Operative | 1 | 2014 | 258 | 0.360 |
Why?
| | Nitric Oxide | 10 | 2011 | 915 | 0.360 |
Why?
| | Humans | 56 | 2025 | 136803 | 0.360 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2002 | 382 | 0.350 |
Why?
| | Intubation, Intratracheal | 2 | 2024 | 257 | 0.340 |
Why?
| | Pulmonary Artery | 11 | 2011 | 1086 | 0.340 |
Why?
| | Parents | 1 | 2019 | 1340 | 0.330 |
Why?
| | Female | 46 | 2025 | 72816 | 0.330 |
Why?
| | Hospitals, Pediatric | 3 | 2024 | 505 | 0.320 |
Why?
| | Anesthesia | 2 | 2023 | 189 | 0.320 |
Why?
| | Persistent Fetal Circulation Syndrome | 2 | 2011 | 137 | 0.300 |
Why?
| | Pregnancy | 23 | 2021 | 6729 | 0.290 |
Why?
| | Survival Rate | 4 | 2018 | 1964 | 0.290 |
Why?
| | Respiration, Artificial | 5 | 2024 | 642 | 0.290 |
Why?
| | Patient Care Bundles | 2 | 2019 | 23 | 0.280 |
Why?
| | Lung Diseases | 1 | 2014 | 768 | 0.280 |
Why?
| | Databases, Factual | 6 | 2024 | 1351 | 0.270 |
Why?
| | Nitric Oxide Synthase Type III | 6 | 2007 | 204 | 0.260 |
Why?
| | Fibrin | 1 | 2007 | 81 | 0.260 |
Why?
| | Fetal Diseases | 3 | 2004 | 173 | 0.260 |
Why?
| | Male | 25 | 2025 | 67330 | 0.250 |
Why?
| | Guanylate Cyclase | 4 | 2011 | 37 | 0.240 |
Why?
| | Logistic Models | 6 | 2025 | 2067 | 0.240 |
Why?
| | Pulmonary Alveoli | 2 | 2005 | 405 | 0.230 |
Why?
| | Infection Control | 2 | 2017 | 166 | 0.230 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 278 | 0.230 |
Why?
| | Bradycardia | 2 | 2024 | 55 | 0.230 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2007 | 242 | 0.230 |
Why?
| | Anastomotic Leak | 1 | 2024 | 41 | 0.230 |
Why?
| | Ventilator Weaning | 1 | 2024 | 36 | 0.220 |
Why?
| | Esophageal Atresia | 1 | 2024 | 26 | 0.220 |
Why?
| | Hospital Mortality | 2 | 2019 | 901 | 0.220 |
Why?
| | Stenosis, Pulmonary Vein | 1 | 2024 | 17 | 0.220 |
Why?
| | Tracheoesophageal Fistula | 1 | 2024 | 33 | 0.220 |
Why?
| | North America | 1 | 2025 | 312 | 0.220 |
Why?
| | Blood Culture | 1 | 2024 | 23 | 0.220 |
Why?
| | Cyclic GMP | 4 | 2011 | 93 | 0.210 |
Why?
| | Consensus | 2 | 2024 | 678 | 0.210 |
Why?
| | Laryngoscopy | 1 | 2024 | 109 | 0.200 |
Why?
| | Ductus Arteriosus | 6 | 2008 | 73 | 0.200 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 301 | 0.200 |
Why?
| | Delphi Technique | 1 | 2024 | 273 | 0.190 |
Why?
| | Multivariate Analysis | 4 | 2024 | 1507 | 0.190 |
Why?
| | Hemangioendothelioma | 1 | 2002 | 15 | 0.190 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 113 | 0.180 |
Why?
| | Infant, Small for Gestational Age | 2 | 2025 | 91 | 0.180 |
Why?
| | Time Factors | 7 | 2024 | 6809 | 0.180 |
Why?
| | Patient Handoff | 1 | 2021 | 32 | 0.180 |
Why?
| | Uterus | 1 | 2002 | 215 | 0.180 |
Why?
| | Hepatitis B Vaccines | 1 | 2021 | 45 | 0.180 |
Why?
| | Animals, Newborn | 7 | 2009 | 844 | 0.180 |
Why?
| | Retrognathia | 1 | 2020 | 5 | 0.180 |
Why?
| | Neuromuscular Blockade | 1 | 2021 | 31 | 0.170 |
Why?
| | Severity of Illness Index | 5 | 2024 | 2822 | 0.170 |
Why?
| | Social Determinants of Health | 1 | 2024 | 257 | 0.170 |
Why?
| | Micrognathism | 1 | 2020 | 18 | 0.170 |
Why?
| | Hepatitis B | 1 | 2021 | 70 | 0.170 |
Why?
| | Betamethasone | 1 | 2000 | 20 | 0.170 |
Why?
| | Benzoates | 2 | 2011 | 43 | 0.170 |
Why?
| | Analgesia | 1 | 2021 | 94 | 0.170 |
Why?
| | Vascular Resistance | 6 | 2011 | 372 | 0.160 |
Why?
| | Ventricular Septum | 1 | 2019 | 8 | 0.160 |
Why?
| | Carbon Monoxide | 1 | 2000 | 80 | 0.160 |
Why?
| | Hypothermia | 1 | 2020 | 36 | 0.160 |
Why?
| | United States | 7 | 2025 | 14691 | 0.160 |
Why?
| | Incidence | 2 | 2018 | 2797 | 0.160 |
Why?
| | Cooperative Behavior | 3 | 2017 | 445 | 0.160 |
Why?
| | Food, Fortified | 1 | 2019 | 41 | 0.150 |
Why?
| | Geographic Mapping | 1 | 2019 | 23 | 0.150 |
Why?
| | Neonatology | 1 | 2019 | 29 | 0.150 |
Why?
| | Airway Obstruction | 1 | 2020 | 162 | 0.150 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 926 | 0.150 |
Why?
| | Blood Pressure | 5 | 2019 | 1774 | 0.150 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2011 | 219 | 0.150 |
Why?
| | Animals | 22 | 2011 | 36850 | 0.150 |
Why?
| | Recombinant Proteins | 4 | 2005 | 1350 | 0.140 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 317 | 0.140 |
Why?
| | Perioperative Care | 1 | 2020 | 178 | 0.140 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 169 | 0.140 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2020 | 249 | 0.140 |
Why?
| | Echocardiography, Doppler | 1 | 2018 | 108 | 0.140 |
Why?
| | Housing | 1 | 2019 | 146 | 0.140 |
Why?
| | Odds Ratio | 2 | 2020 | 1066 | 0.130 |
Why?
| | Patient Transfer | 1 | 2019 | 168 | 0.130 |
Why?
| | Premature Birth | 1 | 2020 | 331 | 0.130 |
Why?
| | Heart Arrest | 1 | 2020 | 338 | 0.130 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2017 | 68 | 0.130 |
Why?
| | Continuity of Patient Care | 1 | 2019 | 281 | 0.130 |
Why?
| | Disease Models, Animal | 6 | 2011 | 4282 | 0.130 |
Why?
| | Patient Readmission | 2 | 2019 | 694 | 0.130 |
Why?
| | Echocardiography | 1 | 2019 | 643 | 0.130 |
Why?
| | Infant, Extremely Premature | 1 | 2017 | 66 | 0.130 |
Why?
| | Hemodynamics | 6 | 2011 | 1110 | 0.130 |
Why?
| | Child | 8 | 2023 | 21819 | 0.120 |
Why?
| | Antimicrobial Stewardship | 1 | 2018 | 117 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2000 | 593 | 0.120 |
Why?
| | Communication | 1 | 2021 | 875 | 0.120 |
Why?
| | Risk Adjustment | 1 | 2016 | 78 | 0.120 |
Why?
| | Liver Neoplasms | 1 | 2002 | 785 | 0.120 |
Why?
| | Vasoconstriction | 2 | 2008 | 202 | 0.120 |
Why?
| | Clinical Nursing Research | 1 | 2015 | 13 | 0.120 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 3 | 2011 | 28 | 0.110 |
Why?
| | Enterocolitis, Necrotizing | 2 | 2024 | 38 | 0.110 |
Why?
| | Nitroarginine | 5 | 2006 | 56 | 0.110 |
Why?
| | rho-Associated Kinases | 3 | 2011 | 83 | 0.110 |
Why?
| | Enzyme Activation | 3 | 2005 | 810 | 0.110 |
Why?
| | Pregnancy Complications, Cardiovascular | 2 | 2004 | 78 | 0.100 |
Why?
| | Program Evaluation | 1 | 2017 | 889 | 0.100 |
Why?
| | Premedication | 2 | 2024 | 44 | 0.100 |
Why?
| | Heart Defects, Congenital | 1 | 2020 | 833 | 0.100 |
Why?
| | Vascular Endothelial Growth Factors | 2 | 2002 | 79 | 0.100 |
Why?
| | Mothers | 1 | 2019 | 752 | 0.100 |
Why?
| | Isoenzymes | 2 | 2011 | 304 | 0.100 |
Why?
| | Administration, Inhalation | 2 | 2007 | 683 | 0.100 |
Why?
| | Vasodilator Agents | 2 | 2011 | 331 | 0.100 |
Why?
| | Pneumonia | 1 | 2018 | 635 | 0.090 |
Why?
| | Apgar Score | 2 | 2023 | 17 | 0.090 |
Why?
| | Health Services Accessibility | 1 | 2019 | 978 | 0.090 |
Why?
| | Enzyme Inhibitors | 5 | 2009 | 839 | 0.090 |
Why?
| | Guideline Adherence | 3 | 2024 | 546 | 0.090 |
Why?
| | Leadership | 1 | 2015 | 382 | 0.090 |
Why?
| | Pyridines | 4 | 2011 | 506 | 0.080 |
Why?
| | Sulfones | 3 | 2005 | 110 | 0.080 |
Why?
| | Infant, Low Birth Weight | 2 | 2022 | 140 | 0.080 |
Why?
| | Prevalence | 3 | 2024 | 2710 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 1 | 2022 | 3556 | 0.080 |
Why?
| | Chronic Disease | 2 | 2014 | 1786 | 0.080 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2011 | 261 | 0.080 |
Why?
| | Serotonin | 1 | 2011 | 323 | 0.080 |
Why?
| | Pulmonary Wedge Pressure | 2 | 2009 | 69 | 0.080 |
Why?
| | Amides | 2 | 2006 | 93 | 0.070 |
Why?
| | Cohort Studies | 4 | 2021 | 5704 | 0.070 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2009 | 445 | 0.070 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2007 | 22 | 0.070 |
Why?
| | Immunohistochemistry | 2 | 2002 | 1733 | 0.070 |
Why?
| | Estradiol | 2 | 2001 | 518 | 0.070 |
Why?
| | Immediate-Early Proteins | 1 | 2007 | 49 | 0.070 |
Why?
| | Oxadiazoles | 3 | 2011 | 33 | 0.070 |
Why?
| | Cardiovascular Agents | 1 | 2008 | 160 | 0.070 |
Why?
| | Comorbidity | 2 | 2024 | 1614 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2024 | 3540 | 0.060 |
Why?
| | Ligation | 2 | 2002 | 87 | 0.060 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 43 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 2 | 2008 | 916 | 0.060 |
Why?
| | Pyrazoles | 2 | 2005 | 423 | 0.060 |
Why?
| | Risk Factors | 3 | 2024 | 10332 | 0.060 |
Why?
| | Thoracoscopy | 1 | 2024 | 56 | 0.060 |
Why?
| | Hyperoxia | 1 | 2005 | 90 | 0.060 |
Why?
| | Chylothorax | 1 | 2024 | 16 | 0.050 |
Why?
| | Anastomosis, Surgical | 1 | 2024 | 152 | 0.050 |
Why?
| | Noninvasive Ventilation | 1 | 2024 | 51 | 0.050 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2024 | 83 | 0.050 |
Why?
| | Birth Weight | 1 | 2007 | 514 | 0.050 |
Why?
| | Body Weight | 2 | 2005 | 985 | 0.050 |
Why?
| | Video Recording | 1 | 2024 | 180 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 455 | 0.050 |
Why?
| | Homeodomain Proteins | 1 | 2007 | 506 | 0.050 |
Why?
| | Parenteral Nutrition | 1 | 2024 | 107 | 0.050 |
Why?
| | Chromones | 1 | 2002 | 44 | 0.050 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2003 | 91 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 108 | 0.050 |
Why?
| | Linear Models | 1 | 2024 | 846 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2007 | 1044 | 0.050 |
Why?
| | Morpholines | 1 | 2002 | 122 | 0.050 |
Why?
| | Airway Extubation | 1 | 2022 | 57 | 0.050 |
Why?
| | Oligonucleotides | 1 | 2002 | 148 | 0.050 |
Why?
| | Drug Administration Schedule | 2 | 2001 | 785 | 0.050 |
Why?
| | Gastroesophageal Reflux | 1 | 2024 | 234 | 0.050 |
Why?
| | Prostaglandins | 1 | 2001 | 97 | 0.050 |
Why?
| | Estrogen Antagonists | 1 | 2001 | 45 | 0.050 |
Why?
| | Artifacts | 1 | 2022 | 129 | 0.050 |
Why?
| | Respiration | 1 | 2022 | 199 | 0.040 |
Why?
| | Piperazines | 3 | 2011 | 350 | 0.040 |
Why?
| | Pain, Postoperative | 1 | 2023 | 266 | 0.040 |
Why?
| | Soluble Guanylyl Cyclase | 2 | 2011 | 15 | 0.040 |
Why?
| | Image Enhancement | 1 | 2022 | 190 | 0.040 |
Why?
| | Postoperative Period | 1 | 2021 | 343 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2002 | 366 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2011 | 2052 | 0.040 |
Why?
| | Protoporphyrins | 1 | 2000 | 16 | 0.040 |
Why?
| | Injections, Intra-Arterial | 1 | 2000 | 27 | 0.040 |
Why?
| | Prognosis | 2 | 2019 | 4013 | 0.040 |
Why?
| | Airway Management | 1 | 2020 | 52 | 0.040 |
Why?
| | Epinephrine | 1 | 2020 | 139 | 0.040 |
Why?
| | Perioperative Period | 1 | 2020 | 56 | 0.040 |
Why?
| | Benzodiazepines | 1 | 2021 | 153 | 0.040 |
Why?
| | Quinoxalines | 2 | 2011 | 66 | 0.040 |
Why?
| | Pain Management | 1 | 2023 | 348 | 0.040 |
Why?
| | Injections, Intramuscular | 1 | 2000 | 126 | 0.040 |
Why?
| | Proteus | 1 | 2019 | 6 | 0.040 |
Why?
| | Enterobacter | 1 | 2019 | 8 | 0.040 |
Why?
| | Transportation of Patients | 1 | 2020 | 54 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2007 | 1501 | 0.040 |
Why?
| | Colorado | 2 | 2020 | 4515 | 0.040 |
Why?
| | Heart Septal Defects, Ventricular | 1 | 2019 | 42 | 0.040 |
Why?
| | Body Temperature Regulation | 1 | 2020 | 97 | 0.040 |
Why?
| | Aftercare | 1 | 2021 | 207 | 0.040 |
Why?
| | Body Temperature | 1 | 2020 | 221 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2021 | 198 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2020 | 10748 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2007 | 2831 | 0.040 |
Why?
| | Contrast Media | 1 | 2022 | 462 | 0.040 |
Why?
| | Cesarean Section | 1 | 2000 | 183 | 0.040 |
Why?
| | Benchmarking | 1 | 2020 | 183 | 0.040 |
Why?
| | Reference Values | 1 | 2000 | 816 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2001 | 436 | 0.040 |
Why?
| | Ultrasonography, Prenatal | 1 | 2020 | 284 | 0.040 |
Why?
| | Operating Rooms | 1 | 2020 | 123 | 0.040 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2020 | 182 | 0.040 |
Why?
| | Surgical Mesh | 1 | 2018 | 47 | 0.040 |
Why?
| | Blood Vessels | 1 | 2000 | 187 | 0.040 |
Why?
| | Imaging, Three-Dimensional | 1 | 2022 | 576 | 0.040 |
Why?
| | Congenital Abnormalities | 1 | 2018 | 88 | 0.040 |
Why?
| | Sterilization | 1 | 2017 | 24 | 0.040 |
Why?
| | Program Development | 1 | 2020 | 364 | 0.030 |
Why?
| | Drug Utilization | 1 | 2018 | 169 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2002 | 858 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2002 | 1481 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 560 | 0.030 |
Why?
| | Risk Assessment | 2 | 2018 | 3434 | 0.030 |
Why?
| | Acetylcholine | 2 | 2009 | 185 | 0.030 |
Why?
| | Patient Care Team | 1 | 2021 | 626 | 0.030 |
Why?
| | Infant Mortality | 1 | 2017 | 115 | 0.030 |
Why?
| | Regression Analysis | 1 | 2018 | 1022 | 0.030 |
Why?
| | Burns | 1 | 2020 | 325 | 0.030 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 2 | 2005 | 17 | 0.030 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 2 | 2005 | 22 | 0.030 |
Why?
| | Escherichia coli | 1 | 2019 | 807 | 0.030 |
Why?
| | Staphylococcus aureus | 1 | 2019 | 449 | 0.030 |
Why?
| | Sildenafil Citrate | 2 | 2005 | 58 | 0.030 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2001 | 605 | 0.030 |
Why?
| | Purines | 2 | 2005 | 176 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1321 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 993 | 0.030 |
Why?
| | Vaccination | 1 | 2021 | 1377 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2011 | 4192 | 0.020 |
Why?
| | Ketanserin | 1 | 2011 | 12 | 0.020 |
Why?
| | Serotonin 5-HT2 Receptor Antagonists | 1 | 2011 | 10 | 0.020 |
Why?
| | Hysterotomy | 1 | 2011 | 9 | 0.020 |
Why?
| | Receptors, Serotonin | 1 | 2011 | 34 | 0.020 |
Why?
| | Sertraline | 1 | 2011 | 29 | 0.020 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2001 | 77 | 0.020 |
Why?
| | Nitroprusside | 1 | 2011 | 69 | 0.020 |
Why?
| | Fluoxetine | 1 | 2011 | 54 | 0.020 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2003 | 145 | 0.020 |
Why?
| | Kidney | 1 | 2018 | 1467 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 327 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2013 | 556 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 7573 | 0.020 |
Why?
| | Constriction | 1 | 2008 | 47 | 0.020 |
Why?
| | Indoles | 1 | 2011 | 410 | 0.020 |
Why?
| | Signal Transduction | 3 | 2006 | 5077 | 0.020 |
Why?
| | Child, Preschool | 1 | 2022 | 10997 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2008 | 473 | 0.020 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2004 | 46 | 0.010 |
Why?
| | Organ Size | 1 | 2005 | 477 | 0.010 |
Why?
| | Drug Combinations | 1 | 2005 | 343 | 0.010 |
Why?
| | Heart Atria | 1 | 2004 | 137 | 0.010 |
Why?
| | Neovascularization, Physiologic | 1 | 2005 | 178 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 2004 | 412 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 29 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 44 | 0.010 |
Why?
| | Meclofenamic Acid | 1 | 2001 | 10 | 0.010 |
Why?
| | Aorta | 1 | 2004 | 417 | 0.010 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2001 | 21 | 0.010 |
Why?
| | Cyclooxygenase 1 | 1 | 2001 | 27 | 0.010 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 59 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2001 | 79 | 0.010 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2001 | 68 | 0.010 |
Why?
| | Pulmonary Ventilation | 1 | 2001 | 79 | 0.010 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2001 | 155 | 0.010 |
Why?
| | Organ Specificity | 1 | 2001 | 304 | 0.010 |
Why?
| | Cyclooxygenase 2 | 1 | 2001 | 178 | 0.010 |
Why?
| | Ligands | 1 | 2003 | 661 | 0.010 |
Why?
| | Drug Interactions | 1 | 2001 | 407 | 0.010 |
Why?
| | Physical Stimulation | 1 | 2000 | 65 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 2001 | 481 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2486 | 0.010 |
Why?
| | Muscle, Smooth | 1 | 2000 | 155 | 0.010 |
Why?
| | Blotting, Western | 1 | 2001 | 1225 | 0.010 |
Why?
| | Gene Expression | 1 | 2003 | 1500 | 0.010 |
Why?
| | Rats | 1 | 2005 | 5639 | 0.010 |
Why?
|
|
Grover's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|